Mergers & Acquisitions
Satsuma Pharmaceuticals, Inc. (NasdaqGM: STSA)
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Satsuma Pharmaceuticals, Inc. (“Satsuma”) (NasdaqGM: STSA) to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the proposed transaction, shareholders of Satsuma will receive $0.91 in cash, plus one non-tradeable contingent value right (“CVR”) of up to $5.77 per share, for each share of Satsuma that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857, or fill out the form on this page.
Please note that the merger is structured as a tender offer, such that time may be of the essence.